Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech's Immunology/Infectious Disease Deal Maker On Following The Science

Executive Summary

Genentech’s infectious diseases and immunology dealmaker speaks to Scrip about the significance of following the science when it comes to partnering.

Advertisement

Related Content

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs
Roche Pact Is Affirmation Of Affimed Technology
Genentech Mines The Microbiome Again With IBD Deal
Deal Watch: Genentech Gets Down In The Dirt With Lodo Therapeutics
Genentech Bets On Kineta's Early-Stage, Disease-Modifying Pain Therapy
Genentech's early-stage RQx deal marks third 2013 venture exit for Avalon

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124136

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel